诺泰生物(688076) - 2024 Q4 - 年度业绩预告

Financial Projections - The company expects to achieve an operating revenue of RMB 1.6 billion to RMB 1.7 billion in 2024, an increase of RMB 566.45 million to RMB 666.45 million compared to the previous year, representing a year-on-year growth of 54.81% to 64.48%[5]. - The projected net profit attributable to the parent company for 2024 is expected to be between RMB 380 million and RMB 460 million, an increase of RMB 217.06 million to RMB 297.06 million compared to the previous year, indicating a year-on-year growth of 133.22% to 182.32%[5]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses for 2024 is also projected to be between RMB 380 million and RMB 460 million, reflecting a year-on-year growth of 126.05% to 173.64%[5]. - In the previous year (2023), the total profit was RMB 173.13 million, and the net profit attributable to the parent company was RMB 162.94 million[7]. Performance Forecast - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by certified public accountants[6]. - The company has not identified any major uncertainties that could affect the accuracy of the performance forecast as of the announcement date[9]. - Investors are advised that the forecast data is preliminary and the final financial data will be disclosed in the official 2024 annual report[10]. - The performance forecast period is from January 1, 2024, to December 31, 2024[4]. Strategic Focus - The company attributes the significant increase in revenue and profit margins to its competitive advantages in interdisciplinary collaboration and an international business development team[8]. - The company emphasizes its commitment to high-quality and green products as part of its growth strategy[8].